Manufacturing CapabilitiesIovance fully controls their manufacturing capabilities and highlighted the uniqueness of owning their own TIL therapy-dedicated iCTC manufacturing facility.

Revenue GuidanceThe company remains confident in its revenue guidance and is well positioned in the early launch, despite the recent departure of its commercial head, and they see no impact from the Biosecures Act.

Sales GrowthIovance provided reassuring revenue guidance, supporting solid momentum in FY24 and FY25 for Amtagvi/Proleukin, with projected revenues above consensus.

Bears Say

Financial PerformanceA charge of $8.7M in cost of goods sold is related to scrap costs, indicating inefficiencies in manufacturing.

Operational ChallengesProlonged wait times for manufacturing slots are extending time to infusion and potentially limiting patient eligibility, impacting product uptake.

Product LaunchInitial metrics indicate a slow launch, with only about 10-15% of enrolled patients receiving the commercial product in the first quarter since approval.

---

Financials

Annual

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

9.64% Insiders

17.21% Mutual Funds

0.74% Other Institutional Investors

55.56% Public Companies and Individual Investors

Detailed Ownership Overview >

2LB FAQ

What was Iovance Biotherapeutics Inc’s price range in the past 12 months?

Iovance Biotherapeutics Inc lowest stock price was €5.57 and its highest was €16.85 in the past 12 months.

What is Iovance Biotherapeutics Inc’s market cap?

Iovance Biotherapeutics Inc’s market cap is $1.80B.

When is Iovance Biotherapeutics Inc’s upcoming earnings report date?

Iovance Biotherapeutics Inc’s upcoming earnings report date is Feb 26, 2025 which is in 26 days.

How were Iovance Biotherapeutics Inc’s earnings last quarter?

Iovance Biotherapeutics Inc released its earnings results on Nov 07, 2024. The company reported -€0.269 earnings per share for the quarter, beating the consensus estimate of -€0.287 by €0.018.

Is Iovance Biotherapeutics Inc overvalued?

According to Wall Street analysts Iovance Biotherapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Iovance Biotherapeutics Inc pay dividends?

Iovance Biotherapeutics Inc does not currently pay dividends.

What is Iovance Biotherapeutics Inc’s EPS estimate?

Iovance Biotherapeutics Inc’s EPS estimate is -0.25.

How many shares outstanding does Iovance Biotherapeutics Inc have?

Iovance Biotherapeutics Inc has 304,780,800 shares outstanding.

What happened to Iovance Biotherapeutics Inc’s price movement after its last earnings report?

Iovance Biotherapeutics Inc reported an EPS of -€0.269 in its last earnings report, beating expectations of -€0.287. Following the earnings report the stock price went down -20.973%.

Which hedge fund is a major shareholder of Iovance Biotherapeutics Inc?

Currently, no hedge funds are holding shares in DE:2LB

---

Iovance Biotherapeutics Stock Smart Score

Unlock Smart Score

Fundamentals

Return on Equity

-56.65%

Trailing 12-Months

Asset Growth

16.29%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Iovance Biotherapeutics Inc

Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

---

2LB Earnings Call

Q3 2024

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects a strong performance with significant revenue growth, successful commercial adoption of Amtagvi, and positive clinical trial results. Despite net losses and initial challenges in ATC performance, the overall sentiment is positive due to surpassing revenue expectations and a solid financial outlook.Read More>

---

2LB Stock 12 Month Forecast

Average Price Target

€23.01

▲(304.41% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","31":"€31","9.25":"€9.25","16.5":"€16.5","23.75":"€23.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30.4656,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€30.47</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.0110485,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€23.01</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.99305,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€19.99</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,9.25,16.5,23.75,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2024","6":"Jun<br/>2024","9":"Sep<br/>2024","12":"Jan<br/>2025","25":"Jan<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7,8.805046153846154,10.610092307692307,12.415138461538461,14.220184615384614,16.025230769230767,17.830276923076923,19.635323076923076,21.440369230769228,23.245415384615384,25.050461538461537,26.85550769230769,28.660553846153846,{"y":30.4656,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7,8.231619115384616,9.463238230769232,10.694857346153846,11.926476461538462,13.158095576923078,14.389714692307692,15.621333807692308,16.852952923076923,18.084572038461538,19.316191153846155,20.54781026923077,21.779429384615383,{"y":23.0110485,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7,7.999465384615385,8.99893076923077,9.998396153846153,10.997861538461539,11.997326923076923,12.996792307692306,13.996257692307692,14.995723076923078,15.995188461538461,16.994653846153845,17.99411923076923,18.993584615384613,{"y":19.99305,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.56,"date":1698796800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.582,"date":1701388800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.454,"date":1704067200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.174,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.935,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.205,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.312,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.476,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.078,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.455,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.364,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.532,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >

Technical Analysis

Similar Stocks

Bluebird Bio

―

FATE

Fate Therapeutics

―

ADAP

Adaptimmune Therapeutics

―

Compare DE:2LB Stocks >

Best Analysts Covering 2LB

1 Year

Geulah LivshitsChardan Capital

1 Year Success Rate

15/32 ratings generated profit

1 Year Average Return

+17.87%

reiterated a buy rating 12 months ago

Copying Geulah Livshits's trades and holding each position for 1 Year would result in 46.88% of your transactions generating a profit, with an average return of +17.87% per trade.

Best Analyst Covering >

Popular Stocks

---

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Iovance Biotherapeutics (2LB) Stock Price & Analysis

2LB Stock Chart & Stats

Iovance Biotherapeutics News

Bulls Say, Bears Say

Financials

Options Prices

Ownership Overview

2LB FAQ

Iovance Biotherapeutics Stock Smart Score

Analyst Consensus

Blogger Sentiment

Insider Transactions

News Sentiment

Technicals

Fundamentals

Company Description

Iovance Biotherapeutics Inc

2LB Earnings Call

2LB Stock 12 Month Forecast

Average Price Target

Technical Analysis

Best Analysts Covering 2LB

Become an Expert with TipRanks Premium